Karyopharm Therapeutics
KPTI
108 hedge funds and large institutions have $737M invested in Karyopharm Therapeutics in 2018 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 43 increasing their positions, 21 reducing their positions, and 10 closing their positions.
220% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 10
105% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 21
78% more capital invested
Capital invested by funds: $415M → $737M (+$322M)
23% more funds holding
Funds holding: 88 → 108 (+20)
8% more call options, than puts
Call options by funds: $616K | Put options by funds: $572K
0.65% more ownership
Funds ownership: 4.15% → 4.8% (+0.65%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$78.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$24M |
| 3 |
State Street
Boston,
Massachusetts
|
+$22.2M |
| 4 |
BlackRock
New York
|
+$21.4M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$16.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$24.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.51M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$7.52M |
| 4 |
Millennium Management
New York
|
-$3.84M |
| 5 |
JP Morgan Chase
New York
|
-$2.77M |
KPTI Hedge Fund Activity: Q2 2018 in Review
108 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2018, worth a combined $737M — up 78% from $415M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new KPTI positions and 10 closed out — a net gain of 22 holders — while 43 added to existing stakes and 21 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $78.6M. The largest seller was Fidelity Investments, cutting an estimated $24.6M.
- 108 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2018, up from 88 in Q1 2018.
- Funds reported $737M of Karyopharm Therapeutics stock for Q2 2018, up 78% quarter-over-quarter.
- 32 funds opened new Karyopharm Therapeutics positions in Q2 2018 and 10 closed out, a net change of +22 holders.
- The largest Karyopharm Therapeutics buyer in Q2 2018 was Consonance Capital Management, an estimated $78.6M added.
- The largest Karyopharm Therapeutics seller in Q2 2018 was Fidelity Investments, an estimated $24.6M sold.
Based on aggregated 13F filings for Q2 2018.